Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.34 |
| ▸ | MAPT | P10636 | 5/20 | 0.34 |
| ▸ | NPC1 | O15118 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | RAB9A | P51151 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.31 |
| ▸ | NOS1 | P29475 | 2/20 | 0.31 |
| ▸ | NOS2 | P35228 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5831892 | 0.80 | — | — | |
| SCHEMBL5831598 | 0.76 | CA1 (0.38) | CA1CA2CA4CA9SMN1; SMN2 | |
| SCHEMBL8396207 | 0.74 | NOS3 (0.43) | CA1CA2CA4CA9SMN1; SMN2 | |
| Iodide SCHEMBL8867335 | 0.73 | NOS3 (0.45) | CA1CA2CA4CA9NOS3 | |
| SCHEMBL21595593 | 0.71 | KMT2A (0.44) | CA1CA2CA4CA9SMN1; SMN2 | |
| SCHEMBL19149184 | 0.68 | CA1 (0.35) | CA1CA2CA4CA9SMN1; SMN2 | |
| SCHEMBL20657442 | 0.68 | CA1 (0.35) | CA1CA2CA4CA9SMN1; SMN2 | |
| SCHEMBL5831680 | 0.67 | CNR1 (0.40) | MAPTMEN1KMT2AALDH1A1CNR2 | |
| SCHEMBL11879318 | 0.66 | HTR3E (0.56) | CA1CA2CA4CA9MAPT | |
| SCHEMBL21595540 | 0.66 | KDM4E (0.44) | SMN1; SMN2MAPTNPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7084164-B2 | Triazole derivative | ASTELLAS PHARMA, INC. (JP) | 2006-08-01 | — | — | US | disclosed |
| US-7034047-B2 | Triazole derivative | ASTELLAS PHARMA, INC. (JP) | 2006-04-25 | — | — | US | disclosed |
| US-20060025461-A1 | Triazole derivative | ASTELLAS PHARMA INC. | 2006-02-02 | — | — | US | disclosed |
| US-20040214818-A1 | Triazole derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD., MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG | 2004-10-28 | — | — | US | disclosed |
| US-20030216385-A1 | Triazole derivatives | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
| EP-1293503-A1 | TRIAZOLE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214818-A1 | Triazole derivative | SLC18A3, SLC6A3, SLC18A2 | CA1 2621/4885CA2 2540/4885CA4 3978/4885 |
| US-20030216385-A1 | Triazole derivatives | SLC18A3, SLC18A2, SLC6A3 | CA1 2558/4885CA2 2532/4885CA4 3932/4885 |
| US-20060025461-A1 | Triazole derivative | SLC18A3, SLC6A3, SLC18A2 | CA1 2621/4885CA2 2540/4885CA4 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.